SHREVEPORT, La. - Many people are using cheaper versions of popular weight-loss shots like Ozempic and Wegovy.

NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid ...

A federal deadline ending sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to ...

1️⃣ ‘Summer of hell’: What’s typically a key money-making time for airlines could fall short this year. Fears about flying, ...

Eli Lilly plans to pursue approval for its new GLP-1 pill by the end of this year. Fact checked by Nick Blackmer A daily pill ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Novo Nordisk, the company that makes Wegovy and Ozempic, is abruptly ousting its chief executive over concerns the firm is losing ground in the popular weight-loss drug market. The firm's market value ...

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...